Efficacy And Prognosis Of 62 Cases Of T-cell Lymphoma Treated By Chidamide

Objective: To discuss the clinical efficacy and prognostic factors of T cell lymphoma treated by Chidamide.Methods: Therapeutic effect evaluation with Chidamide of 50 cases of Peripheral T-cell lymphoma(PTCL)and 12 cases of T-lymphoblastic lymphoma / Leukemia(TLBL / ALL)patients admitted to the Fujian Medical University Union Hospital from January 1,2007 to February 15,2019,were retrospectively analysed.An analysis was also conducted in their clinical characteristics and related prognostic factors.Results:1.There were 62 cases in total,inlcuding 42 males and 20 females,the ratio of male to female is 2.1 to 1,with a median age of 47 years(16-86 years).we got the complete follow-up data of 59 patients,among them,29 cases were dead(49.2%),and the median overall survival time was 20.7 months(6.5-151 months),the overall survival rates at 1 year,3 years,and 5 years were 77.9%,54.8%,and 50.9%,respectively.2.Efficacy analysis indicated that the total effective rate of Chidamide in the treatment of T-cell lymphoma is 56.5%(35/62),and the median progression-free survival time is 6.9 months(0.3-49.6 months).The total survival rate of PTCL was better than TLBL / ALL,and the difference was statistically significant(P = 0.037),but there was no obvious difference of objective remission rates with 60% vs.41.7% between them(p= 0.250).There was no statistically significant difference in the overall survival rate of different treatment methods(Chidamide alone,accepted as maintenance therapy after HSCT or as pretreatment before HSCT,combined with chemotherapy)between the two groups(p = 0.818).As for the objective remission rate,we can see that there was no significant variation(Fisher’s exact test p-values were 0.74 and 0.46,respectively)in group of PTCL and TLBL/ALL.3.Adverse effects of Chidamide mainly occurred in hematological toxicity and gastrointestinal discomfort.4.The most common initial symptoms of all cases were described as body masses(53%),and 13 cases performed fever with rhinobyon,8 cases had cough with shortness of breath,the rest 8 cases manifested gastrointestinal symptoms.About half of the patients were accompanied by group B symptoms,such as fever,night sweats,and weight loss.5.Univariate analysis indicated that hemophagocytic syndrome(p = 0.017),type of disease(p = 0.037),treat cycles Pre-Chidamide(p = 0.002),and Eastern Cooperative Oncology Group(ECOG)score(p = 0.017)were related to prognosis.;Multivariate analysis showed that Hemophagocytic syndrome,the number of pretreatment courses(<4)before Chidamide,which based on the poor control of disease,were the poor prognostic factors.Conclusion: Both PTCL and TLBL/ALL were safe and effective received Chida-mide as monotherapy or combination therapy.The overall survival rate of PTCL was better than that of TLBL/ALL.Hemophagocytic syndrome and the number o-f pre-treatment courses(less than 4)of Chidamide,were the poor prognosic factors.